Artemis Hospitals
| India | Turchia | Austria | |
| Plasmaferesi | da $4,200 | da $1,200 | da $2,000 |
| Scambio di plasma | da $3,800 | da $3,900 | - |
| Plasmaferesi DFPP | da $1,350 | da $1,850 | - |
| Aferesi terapeutica | da $850 | da $1,350 | - |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Mieloma. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Mieloma e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Mieloma.
Il medico è un ematologo-oncologo altamente esperto presso l'HCG Manavata Cancer Centre, Nashik, con oltre 13 anni di esperienza in leucemia, mieloma multiplo e trapianto di midollo osseo. <\/p>
Laureato con un MBBS presso il Grant Medical College e Sir JJ Hospital, il medico ha ulteriormente perseguito un MD in Patologia presso il Lokmanya Tilak Municipal Medical College, Sion, e Mumbai. <\/p>
Inoltre, il medico possiede un DM in Ematologia Clinica dal Medical College, Calcutta, e ha ricevuto premi per professionalità e duro lavoro, sottolineando la sua reputazione come specialista competente e qualificato.<\/p>
Il medico possiede un MD in Oncologia Radioterapica e lavora come consulente. Specializzandosi in tecniche avanzate di trattamento del cancro, il medico offre servizi tra cui Tomoterapia-H, Acceleratore Lineare e Brachiterapia. Queste modalità sono utilizzate per fornire una terapia radiante precisa, minimizzando i danni ai tessuti sani circostanti e migliorando l'efficacia del trattamento.<\/p>
Multiple myeloma is technically categorized as a chronic condition rather than permanently curable. Modern Indian oncology centers achieve deep, long-term remission using advanced therapies. JCI-accredited facilities offer autologous stem cell transplants and quadruplet drug protocols. These methods focus on controlling the disease for a decade or more.
Bookimed Expert Insight: While India is often selected for its low-cost care, the real advantage is the specialization depth in its largest hubs. For example, Global Hospital Chennai is part of a network serving 2,000,000 patients annually and performs over 18,000 procedures. This massive volume means specialists like Dr. Girish Badarkhe at HCG Manavata manage a highly diverse range of myeloma subtypes. High-volume centers often have better access to trials for bispecific antibodies and CAR-T therapies that are not yet widely commercialized.
Patient Consensus: Patients emphasize that `remission` is the realistic goal and warns that treatment is a marathon, not a sprint. Many note that outcomes improve significantly when choosing a dedicated hematology-oncology specialist rather than a general oncologist.
First-line myeloma treatment in Indian hospitals combines proteasome inhibitors with immunotherapy and stem cell transplants. Centers in Delhi and Bengaluru follow National Cancer Grid protocols. These focus on bortezomib-based triplets. Facilities often hold JCI and NABH accreditations to ensure international safety standards.
Bookimed Expert Insight: India is home to the first indigenous CAR T-cell therapy, NexCAR19. While traditional triplets are standard, hospitals like HCG Manavata and Global Hospital Chennai offer deep expertise in managing complex hematology. Dr. Girish Badarkhe at HCG Manavata alone holds significant experience in leukemia and myeloma. Patients should check if their facility utilizes IBM Watson for oncology to further refine drug selection based on genetic data.
Patient Consensus: Patients emphasize that doctors carefully adjust drug combinations based on kidney health and budget. They note it is important to confirm early if the treatment plan leads toward a stem cell transplant.
Active pharmaceutical ingredients for cancer drugs in India are identical to those in the US and Europe. Indian facilities manufacture 40% of US generics. Clinics use the same compounds like bortezomib and lenalidomide within Joint Commission International-accredited hospitals to ensure global safety standards.
Bookimed Expert Insight: India serves as a global manufacturing hub for complex oncology medications. Large networks like Manipal Hospitals and Apollo Hospitals serve over 1,000,000 patients annually. These facilities often implement the same drug protocols for myeloma as Western centers. Hospitals like HCG Manavata Cancer Centre even use technologies like Tomotherapy-H to complement these medications.
Patient Consensus: Patients note that while drug names change, the molecules remain consistent. Many emphasize that treatment success depends heavily on the oncologist’s experience at high-volume centers.
Myeloma treatment in India typically spans 3 to 12 weeks for international patients. Initial workups often begin within days of arrival. Stem cell transplants require the longest stay. High-volume centers like Apollo Hospitals or Manipal Hospitals expedite staging for visiting patients.
Bookimed Expert Insight: Patients arriving at large networks like Manipal Hospitals often bypass diagnostic delays common in smaller clinics. With over 1,900 doctors and 15 locations, these centers use coordinated hematology teams to finalize treatment plans in under 48 hours. This efficiency is critical for myeloma patients who require immediate induction therapy to manage bone pain or kidney issues.
Patient Consensus: Patients note that Indian hospitals frequently repeat baseline laboratory tests even if prior results are provided. It is important to factor in extra days for verify pathology and secure a second hematology opinion before starting intensive cycles.
Indian hospitals support international medical tourists through comprehensive international patient departments. These divisions provide visa invitation letters, remote video consultations, and detailed treatment plans. Facilities like Apollo Hospital Indraprastha and Manipal Hospitals handle over 1,000,000 international patients annually with dedicated logistics teams.
Bookimed Expert Insight: Data shows that India’s largest networks like Manipal and Apollo serve millions of patients because they operate as health systems, not just single buildings. For complex conditions like myeloma, choosing a facility with over 300+ doctors across 40 specialties, such as Artemis Hospitals, ensures that oncology, hematology, and infectious disease teams are integrated into one coordinated international care plan.
Patient Consensus: Patients emphasize that major private hospitals operate like a managed pipeline. They note that having a single coordinator for imaging, labs, and pharmacy helps minimize time away from home during intensive treatment cycles.
India hosts several high-performing hospitals for myeloma treatment. These include JCI-accredited facilities like Apollo Hospital Indraprastha in Delhi and Artemis Hospitals in Gurgaon. These centres specialise in chemotherapy, immunotherapy, and bone marrow transplants. Most major Indian oncology hubs provide multi-disciplinary care under one roof.
Bookimed Expert Insight: Many patients focus on Delhi or Mumbai. However, centres in Nashik like HCG Manavata Cancer Centre serve 75,000 patients each year. This high volume often leads to faster diagnostic turnaround times. It was also the first NABH-accredited cancer care facility in Maharashtra.
Patient Consensus: Patients note that Mumbai and Delhi hospitals have extremely dedicated doctors. These doctors manage over 1,000 transplants. They recommend gathering full medical records before seeking second opinions from these experienced haematologists.
Multiple myeloma treatment in India focuses on induction therapy and autologous stem cell transplants. Advanced immunotherapy is also used. Patients access targeted protocols using proteasome inhibitors and monoclonal antibodies. Specialist centres like HCG Manavata Cancer Centre and Artemis Hospitals provide these treatments. They follow international JCI and NABH quality standards.
Bookimed Expert Insight: India has become a hub for complex haematology. This is due to major networks like Manipal and Apollo managing over 1,000,000 patients each year. Because of this volume, specialists like Dr Girish Badarkhe gain experience in rare haploidentical transplants. These procedures are often harder to access in smaller regional hospitals elsewhere.
Patient Consensus: Patients in India often start with a four-drug induction regimen including Bortezomib and Dexamethasone. Many note that lowering steroid doses helps manage side effects during stem cell transplant preparation.
CAR-T cell therapy is available for myeloma in India at major oncology hospitals. Indian centres use indigenous CAR-T technologies and international protocols for refractory blood cancers. Doctors such as Dr Girish Badarkhe at HCG Manavata Cancer Centre perform these procedures. They treat complex cases.
Bookimed Expert Insight: Indian clinics such as HCG Manavata Cancer Centre have a distinct advantage. They combine CAR-T with TomoTherapy-H and Versa HD radiation. This multi-modal approach manages complex myeloma cases more effectively than single-therapy protocols. This level of integrated care is often unavailable at smaller regional centres.
Patient Consensus: Patients in India find the three-month recovery period manageable. It feels less intense than traditional stem cell transplants. They highlight the importance of preparing for low immune function and potential IgG infusions. These are common after the CAR-T cells are administered.
Leading Indian medical centres provide the latest myeloma treatments. These include CAR T-cell therapy and immunotherapies like daratumumab. Major hospitals in Delhi, Bengaluru and Chennai specialise in these targeted protocols. Australian patients often access clinical trials for emerging agents like mezigdomide.
Bookimed Expert Insight: India ranks 6th globally for medical requests on Bookimed. Top centres like Manipal Hospitals serve over 2,000,000 patients annually. This massive case volume allows Indian specialists to manage complex myeloma cases with highly refined protocols. Australian patients benefit from this deep clinical experience in major metropolitan hubs.
Patient Consensus: Patients note that standard quadruplet therapy is readily available in India. Clinical trials provide a vital pathway to access newer targeted medications at reduced costs. Seeking a compassionate specialist early is essential for managing side effects and long-term recovery.
Myeloma treatment in India typically lasts 6 to 7 months for the main phases. Initial diagnostics take 5 to 7 days. This is followed by 3 to 6 months of induction chemotherapy. A stem cell transplant requires 3 to 4 weeks of inpatient care.
Bookimed Expert Insight: Indian clinics like HCG Manavata Cancer Centre and Apollo Hospital handle massive patient volumes. This experience allows specialists like Dr Girish Badarkhe to manage complex haploidentical transplants. Their high caseload often leads to faster diagnostic turnaround times compared to smaller facilities.
Patient Consensus: Patients note significant blood report improvements after starting therapy in India. These improvements appear within 4 to 6 weeks. The first 6 weeks post-transplant are physically taxing. However, most patients regain their stamina and reach remission by the 6-month mark.
Patients can obtain expert second opinions for myeloma from leading Indian haematologists. Specialist centres provide reviews for complex cases, including refractory blood cancers and transplant eligibility. Consultations with haematologists typically cost between A$60 and A$70. Many facilities offer virtual reviews of lab results and bone marrow biopsies.
Bookimed Expert Insight: Indian specialists often manage exceptionally high patient volumes, which is vital for rare myeloma subtypes. For instance, Apollo Hospitals serves over 1,000,000 international patients annually. These massive datasets allow haematologists to identify patterns in treatment resistance. Centres with lower volumes might miss these patterns.
Patient Consensus: Patients note that second opinions in India help clarify if autologous transplants are necessary. These procedures are intensive. Virtual consultations are a popular way to access specialists early, before bone damage occurs.
International patients in India benefit from dedicated medical coordination and visa assistance. They also receive specialised logistical support at JCI-accredited facilities. Specialised desks manage airport transfers and local accommodation. Multilingual staff and personal coordinators at clinics like Aster CMI Hospital simplify communication. They assist during complex bone marrow transplant procedures.
Bookimed Expert Insight: Clinics in Mumbai and Bengaluru often achieve higher success. They do so by combining standard induction therapy with advanced diagnostics. Manipal Goa Hospital uses IBM Watson for Oncology with 96% accuracy for lung cancer. This reflects the high-tech diagnostic support available for complex myeloma staging.
Patient Consensus: Patients value the clinical expertise in stem cell therapy. They also find the induction protocols align closely with Australian and international standards. Support for housing and visas is available. However, patients note it is important to proactively request palliative care for side effect management.